Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$20.03
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Movers From Yesterday
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
Hikma Pharmaceuticals PLC ADR (HKMPY)
Ionis Pharmaceuticals
See More Headlines

OPNT Stock Analysis - Frequently Asked Questions

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
11/11/2021
Today
1/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Profitability

Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:OPNT) was last updated on 1/27/2025 by MarketBeat.com Staff
From Our Partners